Sign in

India to resume export of surplus Covid-19 vaccines next month: Mandaviya

COVAX is co-led by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and WHO, and aims at equitable distribution of Covid-19 vaccines, particularly focusing on the low and middle income countries

Updated on: Sep 20, 2021, 16:46:05 IST
Share
Share via
  • facebook
  • twitter
  • linkedin
  • whatsapp
Copy link
  • copy link

India will resume export of vaccines against Coronavirus disease (Covid-19) under the government’s ‘Vaccine Maitri’ initiative from October 2021, the Union health ministry announced on Monday.

An Air India flight carrying doses of Covishield vaccine is seen after its arrival at the Velana International Airport, in Male on January 20, 2021. (File photo)
An Air India flight carrying doses of Covishield vaccine is seen after its arrival at the Velana International Airport, in Male on January 20, 2021. (File photo)

“India will be resuming export of vaccines under Vaccine Maitri in order to fulfil the commitment of India towards COVAX, in line with our motto Vasudhaiva Kutumbakam. The surplus supply of vaccines will be used to fulfil our commitment towards the world for the collective fight against Covid-19,” said Union health minister Mansukh Mandaviya.

COVAX is co-led by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and WHO (World Health Organisation), and aims at equitable distribution of Covid-19 vaccines, particularly focusing on the low and middle income countries.

Also Read | Clinical trial results show Pfizer Covid-19 jab safe for children aged 5-11

Till April-end this year,India exported 66.4 million Covaxin and Covishield vaccine doses that included doses as commercial supplies, grants and supplies to the COVAX facility meant for use in low and middle income countries across the globe.

About the expected production in the coming months, the health minister said that more than 300 million (30 crore) vaccine doses will be produced in the month of October and at least 1 billion (100 crore) in the coming quarter.

While there was no ban on vaccine exports, as neither the health ministry, commerce and industry ministry, department of promotion of industry and internal trade, nor the directorate general of foreign trade issued any formal orders asking to bar export of Covid-19 vaccines from the country, India halted vaccine export after new cases started surging during the second wave in the country.

With the hard second wave that India saw April onwards, India began aggressively vaccinating its population and even expanded coverage to all adults from May 1.

The vaccine supplies have been shipped for as many as 93 countries so far, for health care workers with the United Nations, and also their peacekeepers, as per the ministry of external affairs data.

  • Rhythma Kaul
    ABOUT THE AUTHOR
    Rhythma Kaul

    Rhythma Kaul is the national health editor of the Hindustan Times. She has been reporting on public health, medicine, and medical research, with a particular focus on how government decisions and health system reforms shape people’s lives. Rhythma has over 25 years of journalistic experience. She joined Hindustan Times in 2008, and has since covered everything from pandemics and infectious diseases to cutting‑edge medical research and climate‑related health challenges. Her stories routinely track the work of the Ministry of Health and Family Welfare, department of pharmaceuticals, and key national health programmes, making complex medical science and policy accessible to a wide audience. One of her prominent news breaks has been the 2012 Baby Falak case: A two-year-old brutally battered baby girl was admitted to AIIMS-Delhi with severe head injuries, multiple fractures, human bite marks, and burns. The police investigation revealed this to be a case of multi-state human-trafficking racket. She was profiled by The Wall Street Journal for breaking this story. Rhythma holds a Master’s degree from Jawaharlal Nehru University, Delhi. Prior to Hindustan Times, she worked with the India Today Group. Rhythma can be contacted at rhythma.kaul@hindustantimes.com. Her X handle is @RamblingBrook.Read More